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Identification and characterisation of eight novel
SERPINA1 Null mutations
Ilaria Ferrarotti1,7*†, Tomás P Carroll2†, Stefania Ottaviani1, Anna M Fra3, Geraldine O’Brien2, Kevin Molloy2,
Luciano Corda4, Daniela Medicina5, David R Curran6, Noel G McElvaney2 and Maurizio Luisetti1,7
Abstract
Background: Alpha-1 antitrypsin (AAT) is the most abundant circulating antiprotease and is a member of the
serine protease inhibitor (SERPIN) superfamily. The gene encoding AAT is the highly polymorphic SERPINA1 gene,
found at 14q32.1. Mutations in the SERPINA1 gene can lead to AAT deficiency (AATD) which is associated with a
substantially increased risk of lung and liver disease. The most common pathogenic AAT variant is Z (Glu342Lys)
which causes AAT to misfold and polymerise within hepatocytes and other AAT-producing cells. A group of rare
mutations causing AATD, termed Null or Q0, are characterised by a complete absence of AAT in the plasma. While
ultra rare, these mutations confer a particularly high risk of emphysema.
Methods: We performed the determination of AAT serum levels by a rate immune nephelometric method or by
immune turbidimetry. The phenotype was determined by isoelectric focusing analysis on agarose gel with specific
immunological detection. DNA was isolated from whole peripheral blood or dried blood spot (DBS) samples using
a commercial extraction kit. The new mutations were identified by sequencing all coding exons (II-V) of the
SERPINA1 gene.
Results: We have found eight previously unidentified SERPINA1 Null mutations, named: Q0cork, Q0perugia, Q0brescia,
Q0torino, Q0cosenza, Q0pordenone, Q0lampedusa, and Q0dublin . Analysis of clinical characteristics revealed evidence of the
recurrence of lung symptoms (dyspnoea, cough) and lung diseases (emphysema, asthma, chronic bronchitis) in
M/Null subjects, over 45 years-old, irrespective of smoking.
Conclusions: We have added eight more mutations to the list of SERPINA1 Null alleles. This study underlines
that the laboratory diagnosis of AATD is not just a matter of degree, because the precise determination of the
deficiency and Null alleles carried by an AATD individual may help to evaluate the risk for the lung disease.
Keywords: Alpha-1 antitrypsin deficiency, Q0 mutation, Lung diseases, Serpins
Background
Alpha-1 antitrypsin (AAT) is a serine protease inhibitor,
encoded by the SERPINA1 gene on the long arm of
chromosome 14 at 14q32.1. The gene is comprised of
four coding exons (II, III, IV, and V), three untranslated
exons (Ia, Ib, and Ic) in the 5′ region and six introns.
Following translation, the 24 amino acid signal peptide
is removed and the mature polypeptide is a 394 amino
acid, 52 kDa glycoprotein with three asparagine-linked
carbohydrate side chains [1]. AAT is an acute phase
protein produced predominantly by hepatocytes, but
AAT synthesis also occurs in mononuclear phagocytes,
neutrophils, and airway and intestinal epithelial cells
[2]. Consistent with a role as an important acute phase
reactant, hepatocytes express approximately 200 times
more AAT mRNA than other cells [3] and serum levels
rapidly increase several-fold during the acute phase
response [4]. The primary function of AAT is the regula-
tion of serine proteases, and the chief site of action is the
lungs where it protects the fragile alveolar tissues from
proteolytic degradation during inflammatory responses.
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In addition to its undoubted anti-protease properties,
there is accumulating evidence that AAT plays a key
anti-inflammatory role [5].
Alpha-1 antitrypsin deficiency (AATD) (MIM # 613490)
is an inherited condition caused by mutations within
the polymorphic SERPINA1 gene and is characterised
by decreased serum AAT concentrations. AATD is an
under-diagnosed condition and the majority of cases
remain undiagnosed. The World Health Organisation
(WHO), the American Thoracic Society (ATS), and the
European Respiratory Society (ERS) advocate a targeted
screening approach for the detection of AATD in at risk
populations, specifically chronic obstructive pulmonary
disease (COPD), non-responsive asthma, cryptogenic liver
disease and in first degree relatives of known AATD
patients. Over 100 mutations leading to AAT deficiency
have been identified to date and are associated with
varying degrees of risk for lung and liver disease. AATD is
associated with increased risk of cutaneous panniculitis
[6] and case reports have linked AATD to vasculitis [7],
and Wegener’s granulomatosis [8] with the Z allele over-
represented in subsets of ANCA-associated vasculitis [9].
The most common mutations known to cause AATD
are the dysfunctional Z (Glu342Lys) and S (Glu264Val)
mutations. The Z mutation leads to a severe plasma
deficiency and is the most common clinically significant
allele. The majority of individuals diagnosed with severe
AATD are homozygous for the Z mutation, and have
circulating AAT levels reduced to 10-15% of normal. This
is because the Z mutation prompts the AAT protein
to polymerise and accumulate within the endoplasmic
reticulum of hepatocytes, thus causing impaired secre-
tion [10]. The rate of polymer formation for S is much
slower than Z AAT, leading to reduced retention of
protein within hepatocytes, milder plasma deficiency,
and a negligible risk of disease in MS heterozygotes
[11,12]. However, there is a risk of lung disease in
compound heterozygotes. For example, if the slowly
polymerising S variant of AAT is inherited with a rapidly
polymerising variant such as Z, the two variants when
co-expressed can interact to form heteropolymers, lead-
ing to cirrhosis and plasma deficiency [13].
The ultra rare family of SERPINA1 mutations termed
silent or Null are characterised by a complete absence
of AAT in the plasma. Null (also called Q0) mutations
are caused by a variety of different mechanisms includ-
ing large gene deletions [14], intron mutations [15],
nonsense mutations [16], and frameshift mutations
[17]. In some cases, Null variants are synthesised in the
hepatocytes, but they are rapidly cleared by intracellular
degradation pathways [18]. As Null mutations do not
induce AAT polymerisation, they confer no risk of liver
disease but do confer a particularly high risk of lung
disease [19]. The exact prevalence of Null mutations is
unclear, and is hampered by a lack of general awareness
of AATD and inherent flaws in diagnostic strategies.
We report here eight cases of previously unidentified
Null SERPINA1 mutations in the Italian and Irish
populations.
Methods
The diagnostic algorithm for diagnosis of AATD was
applied as previously reported [20]. The probands were
referred to the Italian or Irish National Reference Centres
for the Diagnosis of AATD, situated in Pavia and Brescia
(Italy), and Dublin (Ireland), respectively. Where possible,
relatives were analysed and family trees were created
(online Additional file 1). Family members included in
the study or their parents gave written informed consent.
All procedures were in accordance with the declaration of
Helsinki and approved by the local ethics committees.
Clinical data were obtained from direct observation or
medical charts.
AAT measurements were performed by a rate immune
nephelometric method (Array 360 System; Beckman-
Coulter) or by immune turbidimetry (Beckman Coulter
AU5400). The phenotype was determined by isoelectric
focusing analysis (IEF) on agarose gel with specific
immunological detection [21]. DNA was isolated from
whole peripheral blood or dried blood spot (DBS) samples
using a commercial extraction kit (DNA IQ System, Pro-
mega or PAXgene Blood DNA kit, PreAnalytix or DNA
Blood Mini kit, Qiagen). The new mutations were identi-
fied by sequencing all coding exons (II-V) of the AATgene
(SERPINA1, RefSeq: NG_008290), as previously described
[20,22], using the CEQ 8800 genetic analysis System
(Beckman Coulter) or the Big Dye Terminator Cycle
Sequencing Kit 3.1 (Applied Biosystem) with the 3130
Genetic Analyzer.
Results
The specific mutations are summarized in Table 1. The
eight new Null mutations have been conventionally
named Q0cork, Q0perugia, Q0brescia, Q0torino, Q0cosenza,
Table 1 Description of the eight new SERPINA1 Null
mutations identified
Variant Mutation
Q0cork T180ACA,delCA > Ter190TAA
Q0perugia V239GTG, delG > Ter241TGA
Q0brescia E257GAG > TerTAG
Q0torino Y297TAT > TerTAA
Q0cosenza Q305CAA > TerTAA
Q0pordenone L327CTG,delT > Ter338TGA
Q0lampedusa V337GTG,delG > Ter338TGA
Q0dublin F370TTT,delT > Ter373TAA
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Q0pordenone, Q0lampedusa, and Q0dublin according to the
birthplaces of the oldest subject carrying each mutation.
Q0brescia, Q0torino and Q0cosenza consist of point muta-
tions in the sequence of coding DNA that result in a
premature stop codon (nonsense mutation). Q0cork,
Q0perugia, Q0pordenone, Q0lampedusa and Q0dublin were
caused by deletions, resulting in frameshift of the reading
frame, and creating premature stop codons (Figure 1).
The genotype, AAT levels, and clinical details of each
proband and their relatives bearing Null mutations are
listed in Table 2.
Q0cork
The proband was a 43 year old female who presented
with cough, dyspnoea and wheeze, and was subsequently
diagnosed with asthma by methacholine challenge test
(Family 1.1 – subject IA, Table 2). A current smoker,
spirometry showed no evidence of airways obstruction
with pre-bronchodilator FEV1 of 2.55 L (95%), FVC
3.12 L (100%), and FEV1/FVC 82%. High resolution
computed tomography (HRCT) of the lungs showed no
evidence of emphysema or bronchiectasis. However,
during routine assessment, the AAT concentration was
found to be unusually low given the apparent MM
phenotype observed on IEF, therefore DNA sequencing
was performed. A deletion of CA in codon 180 ACA
(exon II), present in heterozygosity, was detected. The
deletion causes a frameshift in the reading frame and
generates a premature stop codon (TAA) downstream at
codon 190. The subject was homozygous Val213, there-
fore the novel Q0cork deletion arose on a M1(Val213)
background.
Q0perugia
The proband (Family 2.1 – subject IA, Table 2) was a
60 year old male heavy smoker who developed emphy-
sema before the age of 50. Since his AAT concentration
in plasma was lower than normal, a complete genetic
analysis of AAT was performed. The sequencing of SER-
PINA1 gene revealed the heterozygous deletion of the
first G in the codon 239 GTG (exon III), which causes a
frameshift in the reading frame and the generation of a
premature stop codon (241TGA). The novel mutation
was also detected in a brother. Phenotype analysis and
family pedigree revealed that this Null mutation arose
on M1(Val213) background.
Q0brescia
The probands were two sisters (Family 3.1, Table 2),
both suffering from pulmonary emphysema and COPD.
Their spirometry values showed obstructive defects with
pre-bronchodilator FEV1 of 1.89 and 1.23 L (62% and
38%), FVC 3.38 and 2.11 L (97% and 63%), and FEV1/FVC
64% and 60%, respectively. Direct sequencing revealed
both are homozygous for a point mutation at codon 257
(G >T transversion), changing a GAG (glutamic acid)
codon into a TAG stop codon. Furthermore, both were
homozygous for Alanine polymorphism at position 213
(rs6647), corresponding to the ancestral AAT gene variant
M1(Ala). The familial study was performed on their
two daughters (one from each sister) and their parents
and confirmed the mendelian inheritance, showing het-
erozygosity both for the mutation at position 257 and
for the M1 polymorphism at position 213 for all subjects.
According to the reports of the probands their parents
had no distant relationship, although they were born in
two nearby villages in south-east Italy. Subsequently, this
novel mutation was detected in a patient with severe
AATD who was found to be composite heterozygous
Z/Q0brescia (3.2-IA, Table 2). The proband, born in the
same south-eastern Italian area, was a heavy smoker,
who suffered from dyspnoea on exertion and product-
ive cough, and he developed panlobular emphysema by
the age of 40. His spirometry values showed obstructive
defects with pre-bronchodilator FEV1 of 1.01 L (27%),
FVC 3.36 L (73%), and FEV1/FVC 36%.
Q0torino
In index case 4.1 – IA (Table 2) DNA sequencing revealed
heterozygosity for the S mutation (rs17580) and for a
T > A transversion at codon 297 (TyrTAT >TerTAA) in
exon IV. Analysis of the daughter confirmed that the
Null mutation does not segregate with the S mutation
and it arose on a M1(Val) background. The proband
was a ex-smoker (15 pack/year) with emphysema and
dyspnoea at rest.
Q0cosenza
The proband was a 34 year old healthy male with a
reported low concentration of AAT in plasma during a
routine medical assessment (Family 5.1 – subject IIA,
Table 2). DNA sequencing of the proband revealed
heterozygosity for the S mutation (rs17580) and for a
C > T transition at codon 305 (CAA > TAA) in exon IV.
This transversion results in a premature Stop codon
instead of a glutamine codon. Family screening revealed
that the Null mutation does not segregate with S muta-
tion and that the novel Q0cosenza allele arose on an M2
background. The novel mutation was also detected in a
sister (who carried the S mutation as well), the mother
and an aunt.
Q0pordenone
In index case 6.1 – IIB (Table 2), a deletion of a single T in
codon 327 (exon IV) was discovered by DNA sequencing.
The deletion was heterozygous and no other mutation
was present. It causes a frameshift in the reading frame
and generates a premature stop codon (TGA) 11 codons
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Q0perugia
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Q0cosenza Q0pordenone
Q0dublin
Q0brescia
Q0lampedusa
Q0cork
Figure 1 Genomic sequence chromatograms representing SERPINA1 Null mutations.
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Table 2 Summary of clinical details of Q0 individuals
Case Genotype AAT (g/L) Age at diagnosis (years) Proband/kinship to proband Clinical Pack/year
1.1 – IA M1/Q0cork 0.70 43 proband cough, dyspnoea 15
2.1 - IA M3/Q0perugia 0.83 60 proband emphysema 52
2.1 - IB M3/Q0perugia 0.80 54 brother healthy 22
3.1 – IA M1/Q0brescia 0.70 73 mother chronic bronchitis 0
3.1 – IB M1/Q0brescia 0.71 71 father healthy 0
3.1 – IIA Q0brescia/Q0brescia Undetectable 41 proband emphysema 3
3.1 – IIB Q0brescia/Q0brescia Undetectable 37 proband emphysema 6
3.1 – IIIA M1/Q0brescia 0.70 7 daughter healthy 0
3.1 – IIIB M1/Q0brescia 1.08 10 daughter healthy 0
3.2 - IA Z/Q0brescia 0.20 41 proband emphysema 20
4.1 - IA S/Q0torino 0.71 53 proband emphysema 15
5.1 – IA M2/Q0cosenza 0.80 63 aunt dyspnoea 0
5.1 – IB M2/Q0cosenza 0.85 67 mother asthma 0
5.1 – IIA S/Q0cosenza 0.60 34 proband healthy 4
5.1 – IIB S/Q0cosenza 0.71 43 sister healthy 0
6.1 – IA M2/Q0pordenone 0.55 37 father healthy 0
6.1 – IIA M3/Q0pordenone 0.81 6 brother healthy 0
6.1 – IIB M1/Q0pordenone 0.77 0.5 proband cough 0
6.2 – IA M1/Q0pordenone 0.91 54 proband emphysema ex
6.2 – IIA M1/Q0pordenone 0.78 34 nephew healthy 0
6.2 – IIB M1/Q0pordenone 0.66 24 nephew healthy 0
6.3 – IA M1/Q0pordenone 0.47 69 proband emphysema unknown
6.3 – IIA M1/Q0pordenone 0.81 37 son healthy 0.1
6.4 – IA M3/Q0pordenone 1.30 38 mother healthy (pregnant) 0
6.4 – IIA M2/Q0pordenone 0.78 6 proband healthy 0
7.1 – IA M1/Q0lampedusa 0.62 87 mother emphysema 0
7.1 – IIA M1/Q0lampedusa 0.76 57 sister healthy 0
7.1 – IIB M1/Q0lampedusa 0.80 61 sister healthy 0
7.1 – IIC M1/Q0lampedusa 0.73 55 sister healthy 15
7.1 – IID M1/Q0lampedusa 0.74 51 sister chronic bronchitis 60
7.1 – IIE M1/Q0lampedusa 0.71 48 sister chronic bronchitis 0
7.1 – IIF Q0lampedusa/Q0lampedusa <0.1 46 proband emphysema, asthma 0
7.1 – IIIA M1/Q0lampedusa 1.00 30 niece healthy 0
7.1 – IIIB M2/Q0lampedusa 0.84 39 nephew healthy 10
7.1 – IIIC M1/Q0lampedusa 0.64 33 nephew healthy 24
7.1– IIID M1/Q0lampedusa 0.74 22 nephew healthy 1.5
7.1 – IIIE M1/Q0lampedusa 0.67 15 nephew healthy 0
8.1 – IA M1/Q0dublin 0.74 70 proband bronchiectasis 1
8.1 – IIA M1/Q0dublin 0.64 40 son healthy 0
8.1 – IIB M1/Q0dublin 0.70 34 son recurrent LRTIs 1
8.1 – IIC M1/Q0dublin 1.11 39 daughter healthy 0
Index cases are written in bold.
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downstream. The mutation was also detected in the father
and a brother of the index case. Like in the index case
6.1-IIB, Q0pordenone was identified in heterozygosity
with M alleles coding for normal AAT levels in 3
additional cases (6.2 - IA, 6.3 - IA and 6.4 - IIA), and in
4 relatives (2 nephews of 6.2 - IA, one son of 6.3 - IA
and the mother of 6.4 - IIA). The four families carrying
this novel Null allele were not related, but all subjects
carrying Q0pordenone identified so far were born in the
North-East region of Italy.
Q0lampedusa
DNA sequencing of the 4 exons of SERPINA1 in the
index case (7.1 – IIF, Table 2) revealed a homozygous
deletion of a single G in codon 337 (exon V), occurring in
the background of a normal M2 allele (His101-Val213-
Asp376). This deletion results in a frameshift that produces
an altered reading frame and generates an immediately
adjacent premature stop codon (TGA) at position 338. The
proband was a woman, never smoker, who worked in a
sawmill; she had the first episodes of dyspnoea on exertion
at the age of 35, but suspicion of AATD did not arise
untill ten years later, when HRCT diagnosed centrolobular
emphysema and spirometry detected slight obstruction
with pre-bronchodilator FEV1 of 1.5 (63%), FVC 2.39 L
(85% ), and post-bronchodilator FEV1 of 1.63 (72%), FVC
2.65 L (96%). The consanguinity of the proband’s parents
was excluded, according to the direct report of the
patients; nevertheless, they was born in two small islands
near to Sicily, therefore a founder effect is probable. The
novel mutation Q0lampedusa was subsequently diagnosed in
heterozygous fashion with M alleles coding for normal
AAT levels in 11 out of 23 relatives who were subse-
quently investigated. Direct sequencing of SERPINA1
exons in the remaining family members has confirmed the
segregation of the mutant allele.
Q0dublin
The proband was a 70 year old female who presented
with bronchiectasis and a lower than expected AAT con-
centration given the apparent MM phenotype observed
on IEF analysis (Family 8.1 – subject IC, Table 2). A past
smoker, spirometry showed no evidence of airways obstruc-
tion with pre-bronchodilator FEV1 of 1.44 L (89%), FVC
1.97 L (98%), and FEV1/FVC 73%. HRCT of the lungs
showed bronchiectasis but no evidence of emphysema.
Sequencing identified a deletion of a single T resulting in
a frameshift which alters the reading frame and generates
an adjacent premature stop codon (TAA) at position 373.
The subject was homozygous Val213, therefore the novel
Q0dublin deletion arose on a M1(Val213) background. The
same mutation was detected in heterozygosity in all three
children.
Discussion
Null alleles result from different molecular mechanisms,
including large gene deletions, intron mutations, nonsense
mutations, frameshift mutations due to small insertions or
deletions, and missense mutations associated with amino
acid substitutions in potentially critical structural elements
[23]. The common trait of Null mutations is the total
absence of serum AAT. These mutations are extremely
rare and can be difficult to diagnose, mainly because
isoelectric focusing (IEF), a commonly used diagnostic
method, although not preferred technique for screening
of AATD [24], is not able to detect Null variants, as
they do not produce protein. Therefore, the M/Null
and MM phenotypes are identical when analysed by
isoelectric focusing with only the normal M protein evi-
dent. Secondly, M/Null genotypes can be misclassified
as M homozygotes in many common genotyping assays
[25]. Sequence analysis of SERPINA1 gene is the optimal
technique to detect Null mutations and only the applica-
tion of an efficient and cost-effective diagnostic algorithm
can ensure the diagnosis of a subject heterozygous or
homozygous for Null mutations [20].
The existence of AAT Null alleles was first noted in
the early 1970s by several investigators. The first published
report of a Null SERPINA1 mutation described the case of
a 24 year old man who had advanced pulmonary emphy-
sema and no detectable serum AAT [26]. The first report
of a probable Null SERPINA1 mutation in Ireland was a
case report in 1974 describing a pedigree in which the
proband was Z/Null, a son S/Null and the mother M/Null
[27]. The precise Null mutation was not identified and the
diagnosis was based on the discordant AAT concentra-
tions in his son and mother when compared to phenotype
identified by starch gel electrophoresis. The first report
of a Null mutation of Italian origin was Q0trastevere,
which was detected in an Italian individual with asthma
and emphysema [16].
To date, a total of 26 different Null alleles have been
detected and characterized (Table 3). Many are caused by
premature stop codons, mainly due to nonsense mutations
or insertion/deletion of one-two nucleotides that cause
frameshift of the reading frame and lead to a premature
stop codon. A second group of Null mutations lie in
introns; some of these have been identified in mRNA
splicing sites: Nullwest is characterized by a single G >T
base substitution at position 1 of intron II, which generally
is highly conserved; Nullbonny blue has been described as a
deletion of the previously reported G. Other mutations are
caused by large deletions; examples are Nullisola di procida, a
deletion of a 17Kb fragment that includes exons II-V [14],
and Nullriedenburg, caused by the complete deletion of the
gene [28]. It is well known that an almost full length
molecule is essential for the secretion of AAT, therefore a
truncated protein prevents the secretion itself [18].
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Interestingly, Null mutations can also be induced by a
simple amino acid substitution, like in Nullludwigshafen
(Ile92 > Asn92). This substitution of a polar for a non-
polar amino acid leads to folding impairment, with de-
struction of tertiary structure and therefore intracellular
degradation [42]. In most Null mutations belonging to
this group, it is not clear whether the altered glycopro-
tein is unstable and therefore recognized as defective by
intracellular methabolic pathways and degraded, or if it
is secreted but, due to a very short half-life with rapid
turnover, it cannot be detected by routine diagnostic as-
says. In addition, some Null mutations may yet turn out
to be “secreted” Null. For example, Nullnew hope and
Nullnewport, were defined as Null on the basis of IEF and
protein quantification in a period when molecular diag-
nosis was not widely available. A precedent for incorrect
Null alleles does exist, and includes the well known
Mheerlen, which was originally classified as PiQ0 on the
basis of IEF and protein quantification [44], and Plowell,
previously called Q0cardiff [45].
We describe here eight novel Null mutations in the
coding regions of the SERPINA1 gene. Three (Q0brescia,
Q0torino and Q0cosenza) are nonsense mutations, the
others (Q0cork, Q0perugia, Q0pordenone, Q0lampedusa and
Q0dublin) are frameshift mutations caused by deletion of
one or two nucleotides.
It is worth noting most of the new mutations reported
in this study occur close to other mutations, supporting
the concept of mutational hot spots in the SERPINA1
gene [40]. In fact, Q0brescia occurs in a portion of 27 nu-
cleotides (nine amino acids) in exon III of the gene,
where it is possible to find a conspicuous number of
other mutations: Plowell /Pduarte/Ybarcelona at codon 256,
Q0cairo and Mpisa [46] at codon 259, T/S at codon 264,
and the normal variant Lfrankfurt at codon 255. Q0porde-
none lies in another region of 27 nucleotides together
with other Null (Q0hongkong, Q0new hope) and normal
(Plyon, Psaltlake,) mutations. Q0lampedusa occurs in the
region of 21 nucleotides where, in addition to Z, other
deficient (King, Wbethesda) and normal (Etokyo, Pst.albans)
Table 3 List of the 24 Null mutation SERPINA1 described to date
Mechanism Allele Intron/exon Mutation Reference
Large deletion Q0isola di procida Intron IC g8801,del17.65 kb [14]
Q0riedenburg Exon IC Complete deletion of the gene [28]
Intron mutations Q0savannah Intron IA g.5307_5308ins8bp [29]
Q0porto Intron IC +1G > A [30]
Q0madrid Intron IC +3, insT [31]
Q0west Intron II +1G > T [15]
Q0bonny blue Intron II +1delG [23]
Nonsense mutations Q0kowloon Exon II Y 38TAC > Ter TAA [23]
Q0chillichote Exon II Q 156CAG > Ter TAG [29]
Q0amersfoort or Q0predevoort rs199422210 Exon II Y 160TAC > Ter TAG [19,32]
Q0trastevere Exon III W194 TGG > Ter TGA [16]
Q0bellingham rs199422211 Exon III K 217AAG > Ter TAG [33]
Q0cairo rs1802963 Exon III K 259AAA > Ter TAA [34]
Frameshift mutations Q0milano Exon III K59,del17bp > Ter AAA [35]
Q0soest Exon II T102ACC,del A > Ter 112 TGA [32]
Q0granite falls rs267606950 Exon II YTAC, delC > Ter 160 TAG [36]
Q0hong kong Exon IV L318CTC, del TC > Ter 334 TAA [17]
Q0mattawa rs28929473 Exon V L353 TTA, ins T > Ter 376 TGA [37]
Q0ourem Exon V L 352TTA, ins T > Ter 376 TGA [38]
Q0bolton Exon V P362CCC, delC > Ter 373 TAA [39]
Q0clayton Exon V P 362CCC,ins C > Ter 376 TGA, and M1(Val) [40]
Q0saarbruecken Exon V P362CCC,ins C > Ter 376 TGA, and M1(Ala) [41]
Missense mutations Q0lisbon Exon II T68ACC > I ATC [41]
Q0ludwigshafen rs28931572 Exon II I92ATC > N AAC [42]
Q0newport Exon II G115GGC > S AGC [43]
Q0new hope Exon IV G320GGG > E GAG and E342GAG > L AAG [23]
For intronic mutations, reference sequence was NG_008290; dbSNP identification was reported where present.
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mutations lie. Lastly, Q0dublin is only one nucleotide from
Mheerlen and Mwurzburg mutations and two nucleotides
from Etaurisano [46] deficient alleles.
While Null mutations are extremely rare, the recur-
rence of Q0pordenone and Q0brescia in certain localized
areas, without evidence of consanguinity, may indicate a
relatively high prevalence of each Null allele in these
geographic regions.
Although a discussion of the clinical characteristics of
the Null-bearing subjects presented herein is not the main
purpose of this study, we can draw some interesting
conclusions. Subjects with Null mutations should be con-
sidered a subgroup at particularly high risk of emphysema
within the spectrum of AATD [19]. In support of this,
we report three probands homozygous for Null alleles,
with early onset lung disease, despite absent or modest
smoking history. Interestingly, the clinical importance
of Null heterozygosity has never been investigated. Here
we report evidence of the recurrence of lung symptoms
(dyspnoea, cough) and lung diseases (emphysema, asthma,
chronic bronchitis) in M/Null subjects, over 45 years of
age, irrespective of their smoking habit (Table 2).
Conclusions
Our study has significantly expanded the list of Null
alleles known to occur within the SERPINA1 gene and
underlined the importance of the correct diagnosis of
this group of mutations, because of the particularly high
risk of lung disease.
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